The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor (TANGENT).
 
Hans Gelderblom
Research Funding - Abbisko Therapeutics (Inst); AmmaxBio (Inst); Blueprint Medicines (Inst); Deciphera (Inst); InhibRx (Inst); Ipsen (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Abbisko Therapeutics (Inst); Merck (Inst)
 
Emanuela Palmerini
Consulting or Advisory Role - Deciphera pharmaceuticals, llc cf; SynOX
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Michiel van de Sande
Honoraria - Daiichi Sankyo Europe GmbH; Dicephera Pharmaceuticals, Inc.; Merck KGaA
Research Funding - Implatcast GMbH (Inst)
 
Javier Martin Broto
Leadership - Sarcoma Research Solutions SL
Consulting or Advisory Role - Amgen; Asofarma; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Roche; Tecnofarma
Speakers' Bureau - PharmaMar
Research Funding - Adaptimmune; Amgen (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); CEBIOTEX (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); Pfizer (Inst); PharmaMar; PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar
 
Raul Terés
Speakers' Bureau - PharmaMar
Travel, Accommodations, Expenses - Deciphera; PharmaMar; Roche
 
Madhu Davies
No Relationships to Disclose
 
Elyse Seltzer
No Relationships to Disclose
 
Sander Veltkamp
No Relationships to Disclose
 
Gabriel Tinoco
Consulting or Advisory Role - Deciphera; Deciphera; Deciphera; Deciphera; SynOX